Intraoperative cell salvage: The impact on immune cell numbers.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2023
2023
Historique:
received:
12
04
2023
accepted:
13
07
2023
medline:
3
8
2023
pubmed:
1
8
2023
entrez:
1
8
2023
Statut:
epublish
Résumé
Patient outcomes are influenced by many confounding factors peri-operatively, including the type of surgery, anaesthesia, transfusion, and immune competence. We have previously demonstrated (in-vitro) that compared to allogeneic blood transfusion (ABT), intraoperative cell salvage (ICS) improves immune competence. The peri-operative immune response is complex. Altered or impaired immune responses may predispose patients to develop adverse outcomes (i.e., post-operative wound infection, pneumonia, urinary tract infection etc.) Surgical patients may develop infection, even without the confirmed presence of a definite microbiological pathogen. With all these factors in mind it is important to consider changes in immune cell numbers (and sub-populations) and functional capacity during peri-operative transfusion. In this TRIMICS-Cell (Transfusion Related Immune Modulation and Intraoperative Cell Salvage-Cell numbers) study (n = 17, October 2018-November 2019) we prioritized and analysed peri-operative changes in the number and proportions of immune cell populations and sub-populations (B cells (CD20+), NK (natural killer) cells (CD56+), monocytes (CD14+), T cells (total CD3+ and sub-populations: T helper cells (CD4+), cytotoxic T cells (CD8+), effector T cells (CD4+ CD127+), activated effector T cells (CD4+ CD25+ CD127+) and regulatory T cells (CD4+ CD25+ CD127-)), plasmacytoid dendritic cells (pDC; Lineage-, HLA-DR+, CD11c-, CD123+), classical dendritic cell (cDC) (Lineage-, HLA-DR+, CD11c+), and cDC activation (Lineage-, HLA-DR+, CD11c+), co-stimulatory/adhesion molecules and pDC (CD9+, CD38+, CD80+, CD83+, CD86+, CD123+). Firstly we analysed the whole cohort of study patients and secondly according to the relevant transfusion modality (i.e., three study groups: those who received no transfusion, received ICS only (ICS), or both ICS and allogeneic packed red blood cells (pRBC) (ICS&RBC)), during major orthopaedic surgery. For the whole study cohort (all patients), changes in immune cell populations were significant: leucocytes and specifically neutrophils increased post-operatively, returning towards pre-operative numbers by 48h post-operatively (48h), and lymphocytes reduced post-operatively returning to pre-operative numbers by 48h. When considering transfusion modalities, there were no significant peri-operative changes in the no transfusion group for all immune cell populations studied (cell numbers and proportions (%)). Significant changes in cell population numbers (i.e., leucocytes, neutrophils and lymphocytes) were identified in both transfused groups (ICS and ICS&RBC). Considering all patients, changes in immune cell sub-populations (NK cells, monocytes, B cells, T cells and DCs) and functional characteristics (e.g., co-stimulation markers, adhesion, activation, and regulation) were significant peri-operatively and when considering transfusion modalities. Interestingly DC numbers and functional capacity were specifically altered following ICS compared to ICS&RBC and pDCs were relatively preserved post-operatively following ICS. A transient peri-operative alteration with recovery towards pre-operative numbers by 48h post-surgery was demonstrated for many immune cell populations and sub-populations throughout. Immune cell sub-populations and functional characteristics were similar peri-operatively in those who received no transfusion but changed significantly following ICS and ICS&RBC. Interesting changes that require future study are a post-operative monocyte increase in the ICS&RBC group, changes in cDC considering transfusion modalities, and possibly preserved pDC numbers post-operatively following ICS. Future studies to assess changes in immune cell sub-populations, especially during peri-operative transfusion, while considering post-operative adverse outcomes, is recommended.
Sections du résumé
BACKGROUND
Patient outcomes are influenced by many confounding factors peri-operatively, including the type of surgery, anaesthesia, transfusion, and immune competence. We have previously demonstrated (in-vitro) that compared to allogeneic blood transfusion (ABT), intraoperative cell salvage (ICS) improves immune competence. The peri-operative immune response is complex. Altered or impaired immune responses may predispose patients to develop adverse outcomes (i.e., post-operative wound infection, pneumonia, urinary tract infection etc.) Surgical patients may develop infection, even without the confirmed presence of a definite microbiological pathogen. With all these factors in mind it is important to consider changes in immune cell numbers (and sub-populations) and functional capacity during peri-operative transfusion.
METHODS
In this TRIMICS-Cell (Transfusion Related Immune Modulation and Intraoperative Cell Salvage-Cell numbers) study (n = 17, October 2018-November 2019) we prioritized and analysed peri-operative changes in the number and proportions of immune cell populations and sub-populations (B cells (CD20+), NK (natural killer) cells (CD56+), monocytes (CD14+), T cells (total CD3+ and sub-populations: T helper cells (CD4+), cytotoxic T cells (CD8+), effector T cells (CD4+ CD127+), activated effector T cells (CD4+ CD25+ CD127+) and regulatory T cells (CD4+ CD25+ CD127-)), plasmacytoid dendritic cells (pDC; Lineage-, HLA-DR+, CD11c-, CD123+), classical dendritic cell (cDC) (Lineage-, HLA-DR+, CD11c+), and cDC activation (Lineage-, HLA-DR+, CD11c+), co-stimulatory/adhesion molecules and pDC (CD9+, CD38+, CD80+, CD83+, CD86+, CD123+). Firstly we analysed the whole cohort of study patients and secondly according to the relevant transfusion modality (i.e., three study groups: those who received no transfusion, received ICS only (ICS), or both ICS and allogeneic packed red blood cells (pRBC) (ICS&RBC)), during major orthopaedic surgery.
RESULTS
For the whole study cohort (all patients), changes in immune cell populations were significant: leucocytes and specifically neutrophils increased post-operatively, returning towards pre-operative numbers by 48h post-operatively (48h), and lymphocytes reduced post-operatively returning to pre-operative numbers by 48h. When considering transfusion modalities, there were no significant peri-operative changes in the no transfusion group for all immune cell populations studied (cell numbers and proportions (%)). Significant changes in cell population numbers (i.e., leucocytes, neutrophils and lymphocytes) were identified in both transfused groups (ICS and ICS&RBC). Considering all patients, changes in immune cell sub-populations (NK cells, monocytes, B cells, T cells and DCs) and functional characteristics (e.g., co-stimulation markers, adhesion, activation, and regulation) were significant peri-operatively and when considering transfusion modalities. Interestingly DC numbers and functional capacity were specifically altered following ICS compared to ICS&RBC and pDCs were relatively preserved post-operatively following ICS.
CONCLUSION
A transient peri-operative alteration with recovery towards pre-operative numbers by 48h post-surgery was demonstrated for many immune cell populations and sub-populations throughout. Immune cell sub-populations and functional characteristics were similar peri-operatively in those who received no transfusion but changed significantly following ICS and ICS&RBC. Interesting changes that require future study are a post-operative monocyte increase in the ICS&RBC group, changes in cDC considering transfusion modalities, and possibly preserved pDC numbers post-operatively following ICS. Future studies to assess changes in immune cell sub-populations, especially during peri-operative transfusion, while considering post-operative adverse outcomes, is recommended.
Identifiants
pubmed: 37527263
doi: 10.1371/journal.pone.0289177
pii: PONE-D-23-10523
pmc: PMC10393166
doi:
Substances chimiques
Interleukin-3 Receptor alpha Subunit
0
HLA-DR Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0289177Informations de copyright
Copyright: © 2023 Roets et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
JAMA. 2014 Jun 4;311(21):2181-90
pubmed: 24842135
Braz J Anesthesiol. 2016 Mar-Apr;66(2):133-9
pubmed: 26952220
Ann Surg. 2017 Mar;265(3):539-546
pubmed: 27070934
Cell Transplant. 2020 Jan-Dec;29:963689720966265
pubmed: 33076681
Allergy Asthma Clin Immunol. 2018 Sep 12;14(Suppl 2):49
pubmed: 30263032
Immunity. 2007 Jun;26(6):741-50
pubmed: 17582346
Blood Rev. 2007 Nov;21(6):327-48
pubmed: 17804128
Cell. 2002 Mar 22;108(6):755-67
pubmed: 11955430
Microbes Infect. 2006 Apr;8(5):1382-9
pubmed: 16679040
Crit Care. 2002 Aug;6(4):279-81
pubmed: 12225595
Transfusion. 2005 Jan;45(1):103-10
pubmed: 15647025
Proc Natl Acad Sci U S A. 1999 Dec 7;96(25):14541-6
pubmed: 10588741
Trends Immunol. 2002 Jun;23(6):273-5
pubmed: 12072358
Sci Rep. 2020 Jan 22;10(1):947
pubmed: 31969629
Anaesth Intensive Care. 2019 Sep;47(3_suppl):17-30
pubmed: 31674192
Infect Immun. 1997 Jun;65(6):2283-91
pubmed: 9169765
Nat Immunol. 2005 Apr;6(4):345-52
pubmed: 15785760
Crit Care Med. 1999 Apr;27(4):733-40
pubmed: 10321662
Annu Rev Immunol. 2003;21:29-70
pubmed: 12414723
Anaesthesia. 2018 Sep;73(9):1141-1150
pubmed: 29989144
Cell Commun Signal. 2019 Nov 14;17(1):147
pubmed: 31727175
Crit Care Med. 2006 Feb;34(2):344-53
pubmed: 16424713
Medicine (Baltimore). 2016 Aug;95(31):e4490
pubmed: 27495095
Transfusion. 2007 Sep;47(9):1691-9
pubmed: 17725736
Nat Rev Immunol. 2005 Apr;5(4):331-42
pubmed: 15803152
J Clin Immunol. 2005 Mar;25(2):87-98
pubmed: 15821885
Crit Care. 2012 Jan 20;16(1):R12
pubmed: 22264310
J Trauma. 1998 May;44(5):743-8; discussion 748-9
pubmed: 9603073
Cochrane Database Syst Rev. 2010 Apr 14;(4):CD001888
pubmed: 20393932
Cytometry B Clin Cytom. 2003 May;53(1):54-62
pubmed: 12717692
Blood. 2001 Jul 1;98(1):140-5
pubmed: 11418473
Curr Opin Immunol. 2008 Feb;20(1):52-60
pubmed: 18160272
Cent Eur J Immunol. 2014;39(4):532-7
pubmed: 26155175
J Trauma. 1993 Dec;35(6):844-9
pubmed: 8263980
Crit Care Med. 2004 Nov;32(11):2234-40
pubmed: 15640635
J Leukoc Biol. 2008 Mar;83(3):523-35
pubmed: 17913974
Crit Care. 2002 Aug;6(4):298-305
pubmed: 12225603
Annu Rev Immunol. 2012;30:1-22
pubmed: 22136168
J Surg Res. 2013 Sep;184(1):567-71
pubmed: 23764315
J Exp Med. 2004 Jun 21;199(12):1607-18
pubmed: 15197224
J Arthroplasty. 2017 Jan;32(1):320-325
pubmed: 27682006